Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Protagenic's $5M Placement Shows the Gap Between Windward's IPO and Microcap Funding

Protagenic's $1.5M upfront, up to $5M milestone-linked raise for PT00114 contrasts with Windward's $251.2M IPO and puts a spotlight on staged, warrant-heavy financing.

18 Nov 2026 · CompePharma editorial

What happened

Protagenic Therapeutics (PTIX) announced on November 11, 2026 a private placement of up to $5 million. Only $1.5 million is upfront. Up to $3.5 million more depends on the exercise of milestone-linked warrants. The proceeds are earmarked for IND-enabling work and a Phase 1/2a trial of PT00114, a neuropeptide for generalized anxiety disorder (GAD).

The regulatory backdrop is the main support for the raise. The company says FDA's August 2026 pre-IND responses identified no deficiencies precluding an IND. It targets IND submission in late Q1 2027 and first dosing in Q2 2027. The excerpt we reviewed does not give the investors, pricing, warrant terms or the specific milestones that trigger the additional capital, so the full economics are not yet assessable.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →